ArticleCureus2024
An Invasive Solitary Fibrous Tumor/Hemangiopericytoma Originating From the Falx: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intracranial solitary fibrous tumors (SFTs) and hemangiopericytomas (HPCs) are rare, aggressive tumors typically found along the dural sinuses. Despite their aggressive nature, complete surgical resection remains the most significant factor in reducing recurrence and improving survival. Here, we present the case of a 32-year-old male patient who presented with a new-onset headache and vertigo. Magnetic resonance imaging revealed a 50×37 mm left occipital mass originating from the falx and extending into the tentorium, with heterogeneous enhancement and compression/invasion of the left transverse sinus. Total resection was accomplished using microsurgical techniques, and histopathological analysis confirmed SFT/HPC, classified as WHO Grade II. Given the complete resection, including the venous sinus involvement, adjuvant radiotherapy was deemed unnecessary by the multidisciplinary committee. At the latest follow-up, five years post surgery, the patient showed no residual tumor or recurrence, with a reported overall well-being. Early detection and aggressive management through total resection can significantly improve survival and prognosis in patients with SFTs/HPCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.